HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M800571-MCP200v1 8/6/1424    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Glossary Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Nissum, M. Articles by Gupta, M. B. Search for Related Content PubMed PubMed Citation Articles by Nissum, M. Articles by Gupta, M. B. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 8:1424-1435, 2009.
© 2009 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Research

Functional and Complementary Phosphorylation State Attributes of Human Insulin-like Growth Factor-Binding Protein-1 (IGFBP-1) Isoforms Resolved by Free Flow Electrophoresis

Mikkel Nissum, Majida Abu Shehab^,¶, Ute Sukop, Javad M. Khosravi^||, Robert Wildgruber, Christoph Eckerskorn, Victor K. M. Han^,**, and Madhulika B. Gupta^,**,,

From the BD Diagnostics, Am Klopferspitz 19a, 82152 Planegg, Germany,
Departments of Pediatrics and
**Biochemistry, University of Western Ontario and
Children's Health Research Institute, London, Ontario N6C 2V5, Canada,
||Diagnostic Systems Laboratories Inc., Toronto, Ontario M5G 1L7, Canada

Fetal growth restriction (FGR) is a common disorder in which a fetus is unable to achieve its genetically determined potential size. High concentrations of insulin-like growth factor-binding protein-1 (IGFBP-1) have been associated with FGR. Phosphorylation of IGFBP-1 is a mechanism by which insulin-like growth factor-I (IGF-I) bioavailability can be modulated in FGR. In this study a novel strategy was designed to determine a link between IGF-I affinity and the concomitant phosphorylation state characteristics of IGFBP-1 phosphoisoforms. Using free flow electrophoresis (FFE), multiple IGFBP-1 phosphoisoforms in amniotic fluid were resolved within pH 4.43–5.09. The binding of IGFBP-1 for IGF-I in each FFE fraction was determined with BIAcore biosensor analysis. The IGF-I affinity (K_D) for different IGFBP-1 isoforms ranged between 1.12e–08 and 4.59e–07. LC-MS/MS characterization revealed four phosphorylation sites, Ser(P)⁹⁸, Ser(P)¹⁰¹, Ser(P)¹¹⁹, and Ser(P)¹⁶⁹, of which Ser(P)⁹⁸ was new. Although the IGF-I binding affinity for IGFBP-1 phosphoisoforms across the FFE fractions did not correlate with phosphopeptide intensities for Ser(P)¹⁰¹, Ser(P)⁹⁸, and Ser(P)¹⁶⁹ sites, a clear association was recorded with Ser(P)¹¹⁹. Our data demonstrate that phosphorylation at Ser¹¹⁹ plays a significant role in modulating affinity of IGFBP-1 for IGF-I. In addition, an altered profile of IGFBP-1 phosphoisoforms was revealed between FGR and healthy pregnancies that may result from potential site-specific phosphorylation. This study provides a strong basis for use of this novel approach in establishing the linkage between phosphorylation of IGFBP-1 and FGR. This overall strategy will also be broadly applicable to other phosphoproteins with clinical and functional significance.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?